

Tailored respiratory diagnostic solution

Enabling clinical laboratories to identify multiple respiratory pathogens in the same sample

applied biosystems

Molecular testing for respiratory pathogens helps laboratories detect viral, bacterial, and fungal targets with high sensitivity.

Accurate testing is needed to distinguish respiratory pathogens, such as SARS-CoV-2 and influenza, from each other

Molecular testing for respiratory pathogens helps laboratories maximize sensitivity for common viruses including SARS-CoV-2 and influenza (flu). As the pandemic continues to show signs of unpredictability and volatility, we expect SARS-CoV-2 and its variants to remain with us indefinitely. SARS-CoV-2 now joins the list of respiratory pathogens that pathologists will see in the lab; and since influenza and COVID-19 share symptoms, making a differential diagnosis is even more challenging. With the overlap of COVID-19 and flu season, it is helpful for clinical and public health labs to be equipped with a single test that can detect genetic material from multiple respiratory viruses.

Adoption of multiplex testing assays has grown over the last few years, most notably as a response to the SARS-CoV-2 pandemic. Multiplex testing assays allow laboratories to test for multiple infectious disease targets in a single reaction. This helps providers rule out multiple respiratory infections with one patient sample.

Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B Combo Kit*

- Single test for SARS-CoV-2, influenza A, and influenza B viruses
- Compatible with multiple instruments and available in multiple formats
- Refer to CDC guidance: "CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season."**

Product details	
Regulatory status	EUA
Format	Single-tube multiplex
Targets	SARS-CoV-2 (S and N genes)
	Influenza A (matrix gene)
	Influenza B (matrix gene)
Kit size	1,000 rxns
Throughput	1–94 samples on 96-well plates, 1–382 samples on 384-well plates
Control(s)	MS2 process control + included positive control
Sample type(s)	Nasopharyngeal (NP) swab, anterior nasal swab
Turnaround time	Approx. 3 hours
Instruments	Applied Biosystems™ 7500 Fast Dx, QuantStudio™ 5 (96-well, 0.2 mL), and QuantStudio™ 7 (384-well block) real-time PCR instruments
Software	Applied Biosystems™ Pathogen Interpretive Software
Cat. No.	A49868

Sample collection

Specimens including:

- NP swab
- Anterior nasal swab

Sample prep

KingFisher Flex Purification System with MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit CE-IVD

Real-time PCR

TaqPath COVID-19 Flu A, Flu B Combo Kit and Applied Biosystems™ TaqPath™ 1-Step Multiplex Master Mix (no ROX)

Applied Biosystems real-time PCR instruments:

- 7500 Fast Dx Real-Time PCR System
- QuantStudio 5 Real-Time PCR System (96-well, 0.2 mL)
- QuantStudio 7 Flex Real-Time PCR System (384-well)

Analysis and report

Report generated using Pathogen Interpretive Software

* For *In Vitro* Diagnostic Use. For Emergency Use Authorization Only | Rx Only.

** cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html



Find out more at **thermofisher.com/respiratory**

applied biosystems